A study comparing rivaroxaban or warfarin versus low molecular weight heparin (LMWH) for the treatment of treatment of venous-thromboembolism in cancer patients
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2015
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Sponsors Janssen
- 18 Dec 2015 New trial record
- 07 Dec 2015 According to a Janssen Pharmaceuticals media release, results from this trial were presented at the 2015 American Society of Hematology (ASH) Annual Meeting.
- 07 Dec 2015 Results were published in a Janssen Pharmaceuticals media release.